We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The EXCALIBER-RRMM trial showed significant MRD negativity improvement versus the control arm.
The study continues to assess progression-free survival, overall survival, and safety outcomes.
Bristol Myers Squibb (BMY - Free Report) announced positive data from the late-stage study on iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
The phase III EXCALIBER-RRMM (NCT04975997) is a multicenter, two-stage, randomized, open-label study evaluating the efficacy and safety of iberdomide in combination with Darzalex (daratumumab) and dexamethasone (IberDd) versus Darzalex, bortezomib, and dexamethasone (DVd) in RRMM patients.
The study demonstrated a statistically significant improvement in minimal residual disease (MRD) negativity rates, compared with the control arm, in a planned interim analysis of the MRD endpoint.
More on BMY’s Late-Study on Iberdomide
The EXCALIBER-RRMM study is designed to assess dual-primary endpoints of MRD negativity and progression-free survival (PFS). Additional secondary endpoints include overall survival (OS), overall response rate, duration of response, time to progression, time to next treatment, and health-related quality of life (HR-QoL).
Data from the study showed that the safety profile of iberdomide in combination with daratumumab and dexamethasone is generally consistent with previous studies.
BMY stated that the study will continue without changes to evaluate the other dual primary endpoint of PFS and the key secondary endpoint of OS and safety, in accordance with the trial design and based on the recommendations from the Data Monitoring Committee.
Per BMY, iberdomide represents the first of a novel class of medicines, called CELMoDs, which has the potential to create a new foundation for multiple myeloma treatment that may be combined with other therapies. BMY plans to discuss these results with health authorities.
Bristol Myers is looking to expand its pipeline/portfolio, as the legacy portfolio is being adversely impacted due to the continued generic impact on Revlimid, Pomalyst, Sprycel, and Abraxane.
Shares of Bristol Myers have lost 17.8% year to date against the industry’s growth of 5.2%.
Image Source: Zacks Investment Research
BMY collaborated with BioNTech (BNTX - Free Report) in June 2025. Pumitamig is being jointly developed by BioNTech and BMY.
BMY and partner BNTX recently presented interim data from a global randomized mid-stage study evaluating pumitamig plus chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).
Pumitamig is a novel investigational bispecific antibody, combining two complementary, validated mechanisms in oncology into one single molecule. The interim analysis included 43 patients with untreated ES-SCLC (Cohort 1) who received pumitamig in combination with standard-of-care chemotherapy at two dose levels. Data from the phase II study showed a 76.3% confirmed objective response rate, 100% disease control rate and a median progression-free survival of 6.8 months.
The positive data underscore the efficacy of the combination and confirm the dose selection for the ongoing global pivotal late-stage ROSETTA LUNG-01 study.
BMY had earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults. The drug was approved under the brand name Cobenfy.
The approval of Cobenfy for schizophrenia broadens BMY’s portfolio and validates the acquisition of Karuna Therapeutics.
Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades.
Approval of additional new drugs and label expansion of top drugs should further diversify its pipeline.
The Zacks Consensus Estimate for 2025 EPS has increased 70 cents to $6.18 in the past 90 days. Shares of Halozyme have surged 62.3% year to date.
HALO’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.74%.
ANI Pharmaceuticals
ANIP’s shares have gained 72.5% so far this year. Earnings estimates for 2025 have risen 82 cents in the past 60 days. ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
Key Takeaways
Bristol Myers Squibb (BMY - Free Report) announced positive data from the late-stage study on iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
The phase III EXCALIBER-RRMM (NCT04975997) is a multicenter, two-stage, randomized, open-label study evaluating the efficacy and safety of iberdomide in combination with Darzalex (daratumumab) and dexamethasone (IberDd) versus Darzalex, bortezomib, and dexamethasone (DVd) in RRMM patients.
The study demonstrated a statistically significant improvement in minimal residual disease (MRD) negativity rates, compared with the control arm, in a planned interim analysis of the MRD endpoint.
More on BMY’s Late-Study on Iberdomide
The EXCALIBER-RRMM study is designed to assess dual-primary endpoints of MRD negativity and progression-free survival (PFS). Additional secondary endpoints include overall survival (OS), overall response rate, duration of response, time to progression, time to next treatment, and health-related quality of life (HR-QoL).
Data from the study showed that the safety profile of iberdomide in combination with daratumumab and dexamethasone is generally consistent with previous studies.
BMY stated that the study will continue without changes to evaluate the other dual primary endpoint of PFS and the key secondary endpoint of OS and safety, in accordance with the trial design and based on the recommendations from the Data Monitoring Committee.
Per BMY, iberdomide represents the first of a novel class of medicines, called CELMoDs, which has the potential to create a new foundation for multiple myeloma treatment that may be combined with other therapies. BMY plans to discuss these results with health authorities.
BMY’s Efforts to Broaden Portfolio
BMY’s Growth Portfolio comprises drugs like Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Abecma, Sotyku, Krazati and Cobenfy.
Bristol Myers is looking to expand its pipeline/portfolio, as the legacy portfolio is being adversely impacted due to the continued generic impact on Revlimid, Pomalyst, Sprycel, and Abraxane.
Shares of Bristol Myers have lost 17.8% year to date against the industry’s growth of 5.2%.
Image Source: Zacks Investment Research
BMY collaborated with BioNTech (BNTX - Free Report) in June 2025. Pumitamig is being jointly developed by BioNTech and BMY.
BMY and partner BNTX recently presented interim data from a global randomized mid-stage study evaluating pumitamig plus chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).
Pumitamig is a novel investigational bispecific antibody, combining two complementary, validated mechanisms in oncology into one single molecule. The interim analysis included 43 patients with untreated ES-SCLC (Cohort 1) who received pumitamig in combination with standard-of-care chemotherapy at two dose levels. Data from the phase II study showed a 76.3% confirmed objective response rate, 100% disease control rate and a median progression-free survival of 6.8 months.
The positive data underscore the efficacy of the combination and confirm the dose selection for the ongoing global pivotal late-stage ROSETTA LUNG-01 study.
BMY had earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults. The drug was approved under the brand name Cobenfy.
The approval of Cobenfy for schizophrenia broadens BMY’s portfolio and validates the acquisition of Karuna Therapeutics.
Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades.
Approval of additional new drugs and label expansion of top drugs should further diversify its pipeline.
BMY's Zacks Rank & Stocks to Consider
Bristol Myers currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Halozyme Therapeutics (HALO - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , both carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Halozyme Therapeutics
The Zacks Consensus Estimate for 2025 EPS has increased 70 cents to $6.18 in the past 90 days. Shares of Halozyme have surged 62.3% year to date.
HALO’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.74%.
ANI Pharmaceuticals
ANIP’s shares have gained 72.5% so far this year. Earnings estimates for 2025 have risen 82 cents in the past 60 days. ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%.